Found: 2
Select item for more details and to access through your institution.
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
- Published in:
- Journal of Clinical Medicine, 2021, v. 10, n. 5, p. 1005, doi. 10.3390/jcm10051005
- By:
- Publication type:
- Article
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2023, v. 115, n. 7, p. 796, doi. 10.1093/jnci/djad061
- By:
- Publication type:
- Article